An Edison, NJ-based company that specializes in TLR7/8 programs to treat cancer and has built a comprehensive global intellectual property portfolio in the category of toll-like receptor modulators.

The company is progressing a proprietary pipeline of cancer therapeutics, with the lead product BDB001 in Phase I clinical trials in the USA.

In June 2019, Seven and Eight signed a clinical research collaboration to test BDB001 alongside Roche's Tecentriq (atezolizumab).